Citi Lifts Travere Therapeutics (TVTX) PT to $34 on Strong Q2 and Upcoming FDA Catalysts

Travere Therapeutics Inc. (NASDAQ:TVTX) is one of the best small cap stocks with biggest upside potential. On August 10, Citi raised the price target on Travere Therapeutics to $34 from $32, while maintaining a Buy rating on the shares. The firm sees meaningful potential upside for the shares with two near-term FDA action dates for Travere.

Before this decision, Travere Therapeutics reported its Q2 2025 financial results, with a revenue of $114.4 million, up from $54.1 million in Q2 2024. This was driven by a 165% year-over-year growth in US net product sales of FILSPARI, which reached $71.9 million. The company also received a $17.5 million milestone payment from its partner, CSL Vifor, during the quarter.

A laboratory technician working on a solution of rare diseases, housed in a cholic acid capsule.

Earlier in May, the FDA accepted the company’s supplemental new drug application/sNDA for FILSPARI for the treatment of focal segmental glomerulosclerosis/FSGS, setting a PDUFA target action date of January 13, 2026. If approved, FILSPARI would be the first FDA-approved treatment for FSGS. Furthermore, the company expects a PDUFA action date of August 28 this year for its sNDA to modify the FILSPARI REMS (Risk Evaluation and Mitigation Strategy) program, which would remove the embryo-fetal toxicity monitoring requirement and reduce the frequency of liver monitoring.

Travere Therapeutics Inc. (NASDAQ:TVTX) is a biopharmaceutical company that identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the US.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.